

## Lipidor completes planned divestment of shares in Emollivet

**STOCKHOLM, Sweden, 26th March 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the remaining holding of shares in Emollivet AB has been divested according to plan and amounting to 467 KSEK.**

As previously announced, Lipidor has carried out a phased divestment of its holding in Emollivet AB. As of today, the remaining part, corresponding to 64 shares in Emollivet ("Emollivet Shares"), has been sold at a price per share of 7,290 SEK and the transaction provides Lipidor with 467 KSEK.

The decision to carry out the sale is part of securing short-term cash for Lipidor, and the divestment of Emollivet shares has been the best option for this purpose. The price per Emollivet Share has been determined on the basis of the valuation opinion previously issued by an independent party.

The sale of the Emollivet shares is distributed among four buyers, all of whom are existing shareholders in Emollivet AB and three of the four buyers, together representing just under half of the total value of the transaction, are also represented on Lipidor's Board of Directors. These buyers being Fredrik Sjövall (5 shares), Ola Flink (15 shares) and Otto Skolling (10 shares).

### **For more information, please contact:**

Ola Holmlund, CEO  
Telephone: +46 (0) 72 50 70 369  
Email: [ola.holmlund@lipidor.se](mailto:ola.holmlund@lipidor.se)

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

### **About Lipidor AB**

Lipidor AB (Nasdaq First North Growth Market: LIPI) ([www.lipidor.se](http://www.lipidor.se)) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor's priority project is AKP02G2, which focusses on psoriasis.

*This information is information that Lipidor AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-03-26 12:52 CET.*

**Attachments**

**Lipidor completes planned divestment of shares in Emollivet**